Ionis Pharmaceuticals (IONS) Operating Leases (2021 - 2026)

Ionis Pharmaceuticals' Operating Leases history runs 6 years deep, the most recent figure standing at $259.2 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 62.63% year-over-year to $259.2 million in Q1 2026; TTM through Mar 2026 was $259.2 million, a 62.63% increase from a year earlier, with the FY2025 full-year figure at $262.4 million, up 62.16% from the prior year.
• Operating Leases fell to $259.2 million in Q1 2026 per IONS's latest filing, from $262.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $262.7 million in Q3 2025 and bottomed at $159.4 million in Q1 2025.
• The 5-year median for Operating Leases is $172.0 million (2023), against an average of $189.2 million.
• Across the five-year window, Operating Leases surged 820.86% in 2022 and fell 5.5% in 2025, its largest moves.
• Year by year, Operating Leases stood at $178.9 million in 2022, then decreased by 4.51% to $170.9 million in 2023, then dropped by 5.31% to $161.8 million in 2024, then surged by 62.16% to $262.4 million in 2025, then decreased by 1.21% to $259.2 million in 2026.
• Per Business Quant, the three latest IONS Operating Leases figures stand at $259.2 million (Q1 2026), $262.4 million (Q4 2025), and $262.7 million (Q3 2025).